BioCentury | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

...company in November to become CMO of Sigilon Therapeutics Inc. (Cambridge, Mass.). Rare disease company ArTara...
BioCentury | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

...Roberts. Roberts was VP of R&D at Eli Lilly and Co. (NYSE:LLY). Rare disease company ArTara...
Items per page:
1 - 2 of 2
BioCentury | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

...company in November to become CMO of Sigilon Therapeutics Inc. (Cambridge, Mass.). Rare disease company ArTara...
BioCentury | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

...Roberts. Roberts was VP of R&D at Eli Lilly and Co. (NYSE:LLY). Rare disease company ArTara...
Items per page:
1 - 2 of 2